OVULEN-28 (ethynodiol diacetate; mestranol) by Pfizer is clinical pharmacology combination oral contraceptives act primarily by suppression of gonadotropins. Approved for pregnancy in women. First approved in 1967.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
OVULEN-28 is a combination oral contraceptive containing ethynodiol diacetate and mestranol, approved in 1967 for prevention of pregnancy in women. It works primarily by suppressing gonadotropins to inhibit ovulation, while also altering cervical mucus and endometrial tissue to reduce sperm entry and implantation likelihood.
As a legacy product nearing loss of exclusivity with minimal current spending tracked, brand teams face resource constraints and likely workforce rationalization.
CLINICAL PHARMACOLOGY Combination oral contraceptives act primarily by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations in the genital tract, including changes in the cervical mucus (which increase the difficulty of sperm…
Zero linked job openings reflect the product's terminal commercial stage; roles on OVULEN-28 are largely maintenance-focused (portfolio stewardship, managed care negotiations) rather than growth-oriented. Career advancement from this assignment is limited unless pivoting to adjacent contraceptive portfolios or Pfizer's newer women's health initiatives.
Worked on OVULEN-28 at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.